| Literature DB >> 19436607 |
Ilias Georgalas1, Petros Petrou, George Kalantzis, Dimitrios Papaconstantinou, Chrysanthi Koutsandrea, Ioannis Ladas.
Abstract
PURPOSE: To evaluate the efficacy and safety of Neodymium:YAG (Nd:YAG) laser capsulotomy for posterior capsule opacification (PCO) following combined phacoemulsification and vitrectomy for the treatment of cataract in association with macular hole (MH) or epiretinal membrane (ERM).Entities:
Year: 2009 PMID: 19436607 PMCID: PMC2697513 DOI: 10.2147/tcrm.s4754
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Data for patients treated with Nd:YAG capsulotomy
| Case | Age (yr) | Sex | Condition | Follow-up (M) | VA pre-YAG | VA post-YAG |
|---|---|---|---|---|---|---|
| 1 | 56 | Male | ERM | 6 | 20/63 | 20/40 |
| 2 | 77 | Male | ERM | 8 | 20/80 | 20/40 |
| 3 | 78 | Female | ERM | 17 | 20/50 | 20/25 |
| 4 | 67 | Female | ERM | 18 | 20/50 | 20/40 |
| 5 | 64 | Female | ERM | 13 | 20/40 | 20/25 |
| 6 | 65 | Female | ERM | 12 | 20/80 | 20/40 |
| 7 | 53 | Male | ERM | 7 | 20/63 | 20/40 |
| 8 | 62 | Female | MH | 7 | 20/100 | 20/63 |
| 9 | 54 | Male | MH | 4 | 20/40 | 20/40 |
| 10 | 58 | Male | ERM | 5 | 20/50 | 20/25 |
| 11 | 78 | Male | MH | 19 | 20/100 | 20/63 |
| 12 | 83 | Male | VTS | 15 | 20/60 | 20/40 |
| 13 | 45 | Male | ERM | 8 | 20/40 | 20/25 |
| 14 | 56 | Male | MH | 5 | 20/40 | 20/40 |
| 15 | 67 | Male | VTS | 7 | 20/100 | 20/40 |
| 16 | 65 | Male | ERM | 10 | 20/50 | 20/40 |
| 17 | 54 | Male | MH | 14 | 20/32 | 20/25 |
| 18 | 87 | Male | MH | 12 | 20/100 | 20/63 |
| 19 | 76 | Male | ERM | 15 | 20/63 | 20/40 |
| 20 | 65 | Female | ERM | 10 | 20/50 | 20/32 |
| 21 | 66 | Male | ERM | 5 | 20/80 | 20/32 |
| 22 | 51 | Female | ERM | 5 | 20/80 | 20/40 |
| 23 | 59 | Female | ERM | 4 | 20/80 | 20/32 |
| 24 | 72 | Female | VTS | 19 | 20/100 | 20/40 |
| 25 | 77 | Female | MH | 21 | 20/40 | 20/32 |
| 26 | 69 | Male | ERM | 23 | 20/63 | 20/40 |
| 27 | 61 | Female | MH | 19 | 20/100 | 20/80 |
| 28 | 59 | Male | ERM | 10 | 20/80 | 20/40 |
| 29 | 55 | Female | ERM | 5 | 20/100 | 20/63 |
| 30 | 67 | Female | MH | 18 | 20/40 | 20/32 |
| 31 | 78 | Male | MH | 12 | 20/100 | 20/40 |
| 32 | 59 | Male | MH | 8 | 20/63 | 20/40 |
| 33 | 51 | Female | MH | 9 | 20/40 | 20/25 |
| 34 | 79 | Female | VTS | 6 | 20/100 | 20/40 |
Abbreviations: ERM, epiretinal membrane; MH, macular hole; VA, visual acuity; VTS, vitreomacular traction syndrome.
Note: Follow-up is measured in months, age is measured in years.
Table demonstrating the time elapsed between combined vitrectomy–phacoemulsification and posterior capsule opacification
| Time until PCO
| |||
|---|---|---|---|
| Case | ERM | MH | |
| 1 | 10 | 12 | |
| 2 | 5 | 18 | |
| 3 | 6 | 17 | |
| 4 | 9 | 10 | |
| 5 | 11 | 19 | |
| 6 | 12 | 9 | |
| 7 | 5 | 19 | |
| 8 | 8 | 14 | |
| 9 | 11 | 16 | |
| 10 | 8 | 15 | |
| 11 | 14 | 18 | |
| 12 | 18 | 17 | |
| 13 | 6 | ||
| 14 | 9 | ||
| 15 | 11 | ||
| 16 | 12 | ||
| 17 | 19 | ||
| 18 | 6 | ||
Abbreviations: ERM, epiretinal membrane; MH, macular hole; PCO, posterior capsule opacification.
Note: Time until PCO is measured in months.